Table 3.
Prevalence of DEP Among C-HBVI Cases
| Overall | DEP | HBeAg+/Anti-HBe- | HBeAg-/Anti-HBe+ | HBeAg-/Anti-HBe- | |||||
|---|---|---|---|---|---|---|---|---|---|
| N | n | Prevalence (%) (95% CI) | n | Prevalence (%) (95% CI) | n | Prevalence (%) (95% CI) | n | Prevalence (%) (95% CI) | |
| Age (years old) | |||||||||
| < 45 | 1134 | 91 | 8.0 (6.4–9.6) | 450 | 39.7 (36.8–42.5) | 573 | 50.5 (47.6–53.4) | 20 | 1.8 (1.0–2.5) |
| ≥ 45 | 1686 | 74 | 4.4 (3.4–5.4) | 238 | 14.1 (12.5–15.8) | 1330 | 78.9 (76.9–80.8) | 44 | 2.6 (1.8–3.4) |
| Gender | |||||||||
| Male | 1898 | 118 | 6.2 (5.1–7.3) | 445 | 23.4 (21.5–25.4) | 1292 | 68.1 (66.8–70.7) | 43 | 2.3 (1.6–2.9) |
| Female | 922 | 47 | 5.1 (3.7–6.5) | 243 | 26.4 (23.5–29.2) | 611 | 66.3 (63.2–69.3) | 21 | 2.3 (1.3–3.2) |
| Treatment | |||||||||
| Treatment naive | 2129 | 120 | 5.6 (4.7–6.6) | 510 | 24.0 (22.1–25.8) | 1464 | 68.8 (66.8–70.7) | 35 | 1.6 (1.1–2.2) |
| Treatment experienced | 691 | 45 | 6.5 (4.7–8.4) | 178 | 25.8 (22.5–29.0) | 439 | 63.5 (59.9–67.1) | 29 | 4.2 (2.7–5.7) |
| Immune statement | |||||||||
| Immune-tolerant | 87 | 5 | 5.7 (0.9–10.6) | 82 | 94.3 (89.4–99.1) | ||||
| Immune-active | 727 | 78 | 10.7 (8.5–13.0) | 281 | 38.7 (35.1–42.2) | 363 | 49.9 (46.3–53.6) | 5 | 0.7 (0.1–1.3) |
Abbreviations: DEP, dual-positivity for both hepatitis B e antigen and hepatitis B e antibody; C-HBVI, chronic hepatitis B virus infection; HBeAg, hepatitis B e antigen; anti-HBe, hepatitis B e antibody.